Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 7Uterine Cervical Neoplasms 5Neoplasms 4Esophageal Neoplasms 4Brain Neoplasms 4Thyroid Neoplasms 3Neuroendocrine Tumors 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2Testicular Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Melanoma 2Lung Neoplasms 2Hematologic Neoplasms 2Glioblastoma 2Carcinoma, Transitional Cell 2Astrocytoma 2Adrenal Gland Neoplasms 2Vaginal Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1

Interventions

Cyclophosphamide 27Rituximab 26fludarabine phosphate 18Filgrastim 17fludarabine 13Lenalidomide 13Peripheral Blood Stem Cell Transplantation 12Bortezomib 12Bendamustine Hydrochloride 12ibrutinib 9venetoclax 8Etoposide 8Paclitaxel 7Flow Cytometry 7Cyclosporine 7tanespimycin 6aldesleukin 6Prednisone 6Magnetic Resonance Spectroscopy 6Cytarabine 6Biopsy 6obinutuzumab 5Vorinostat 5Tacrolimus 5Radiotherapy 5Polymerase Chain Reaction 5Melphalan 5Gemcitabine 5sargramostim 4belinostat 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, B-Cell, Marginal Zone × Fluorodeoxyglucose F18 × Clear all
NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Mayo Clinic

Phase 1 Terminated
17 enrolled
BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡